Restriction on the Supply of Dexamphetamine—Approval to Prescribe, Supply and Administer (Approval No.: 2015/AP002)
Pursuant to Regulation 22 of the Misuse of Drugs Regulations 1977, I, Michael Haynes, Team Leader, Medicines Control, Ministry of Health, acting under delegated authority from the Minister of Health, hereby make the following approval:
That dexamphetamine (a controlled drug described in Part 1 of Schedule 2 of the Misuse of Drugs Act 1975) may be prescribed or supplied or administered by the classes of persons described, and in the circumstances set out in the following Schedule.
I hereby revoke the approval to prescribe, supply and administer dexamphetamine (No. 2008/Dex/1) that was issued on 17 October 2008 and which took effect from 1 December 2008.
Schedule
Prescribing
From 12 February 2015:
The following class of persons (“vocational medical practitioners”) may prescribe dexamphetamine products for a patient under his or her care for the corresponding conditions:
Any other medical practitioner registered with the Medical Council of New Zealand (“registered medical practitioner”), or nurse practitioner registered with the Nursing Council of New Zealand practising within their area of practice (“nurse practitioner”), may only prescribe dexamphetamine products when acting on the written recommendation of one of the vocational medical practitioners described above, for the conditions specified.
Supply
From 12 February 2015:
The following class of persons may supply dexamphetamine products in the following circumstances:
Any pharmacist registered with the Pharmacy Council of New Zealand under the Health Practitioners Competence Assurance Act 2003, in the course of his or her employment as a pharmacist, may supply dexamphetamine products pursuant to a prescription issued by:
Administration
From 12 February 2015:
Any person who is caring for a patient, for whom a dexamphetamine product has been prescribed by any of the medical practitioners or nurse practitioners described in this Schedule, may administer the product to that patient in accordance with the prescribed directions for use.
Dated at Wellington this 5th day of February 2015.
MICHAEL HAYNES, Team Leader Medicines Control, Ministry of Health.